ResearchMoz

Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted

GBI Research
Published Date » 2011-11-22
No. Of Pages » 216

GBI Research, the leading business intelligence provider, has released its latest research Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted which provides an insight into different endpoints that are used for the central nervous system (CNS) in clinical trials. The report examines different aspects under clinical trial endpoints in central nervous system disorders such as analysis on major marketed central nervous system drugs with an emphasis on safety and efficacy details. Phase II and Phase III clinical trial analysis for both completed and ongoing clinical trials, most promising central nervous system drugs with details on safety, efficacy and clinical trials, and terminated trial analysis. The company profiling highlights the central nervous system drugs of different companies.

The global CNS disease market is valued as $53.1 billion in 2010 that grew from $36.8 billion in 2002 with a CAGR of 4.7%. An increased geriatric population in many countries combined with increased life expectancy is expected to increase disease population of CNS disease. The product pipeline of CNS disease is promising with many novel molecules with disease modifying characteristics at various stages of development and is expected to fulfill the unmet needs in the CNS disease market. The product pipeline for multiple sclerosis has many orally administered novel molecules whereas for alzheimers disease, the product pipeline have novel molecules such as Bapineuzumab, Solanezumab, BMS-708163 that target the underlying causes of the disease and thus may offer significant benefits to the patients. 

The market for Schizophrenia and bipolar disorder is estimated to be driven by the anticipated launch of AZ-004 and other molecules such as Cariprazine, Zicronapine, RG1678 and Aripiprazole Depot injection. The continued uptake of non stimulants and expected launch of Kapvay and other pipeline molecules will have significant impact on market for ADHD. Although in upcoming years the market will witness patent expiries of major drugs, however this will be offset by the rapid uptake of new molecules, which will stabilize the market decline. The market is expected to grow with a CAGR of 1.4% from 2010 to 2017 to reach $58.6 billion in 2017.

This report details Endpoints Clinical Trials in Central nervous system Disorders, highlighting the five major central nervous system disorders which are Alzheimers disease, Depression, Epilepsy, Parkinsons disease and Schizophrenia. The classification of five major central nervous system diseases is done on the basis of, the number of pipeline molecules present in Phase III stage of development.

The term endpoint refers to an outcome or measure of a clinical trial. Endpoints can include all kinds of aspects, those related to the effectiveness of treatment and others. However, the endpoint selection must take into account the need to obtain the highest information of therapeutic interest with the least risk and discomfort for the individual. Also, the endpoints must be to the objective of the study and represent the most effective way to assess pharmacological response.

Scope

  • Data and analysis on the marketed products and analysis of their efficacy and safety details
  • Analysis of the five major Central nervous system diseases which include Alzheimers disease, depression, epilepsy, Parkinsons disease and schizophrenia
  • Analysis of the Phase III and Phase II clinical trials in terms of percentage cases. Also analysis of terminated trials is included in this chapter. Only industry sponsored studies are included in the report.
  • Analysis on most promising molecules of five major central nervous system diseases with emphasis on their efficacy and safety details.
  • Company Profiling talks in detail about the companies, which are strong in the market.

Reasons to buy

  • Understand the trends in clinical trial endpoints used for central nervous system diseases
  • Build effective strategies to launch their pipeline products by identifying the right endpoints
  • Understanding and applying Surrogate endpoints and Clinical Biomarkers as endpoints for central nervous system diseases
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with increased efficiency and better safety profiles.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies.
Table of Contents

1 Table of Contents

1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 7

2 Clinical Trial Design in Central Nervous System - Overview 12
2.1 Introduction 12
2.2 Types of Clinical Trial Outcomes 12
2.2.1 Primary Outcomes 12
2.2.2 Secondary Outcomes 12
2.3 GBI Research Report Guidance 13

3 Endpoints - Clinical Trials in CNS Disorders - Top Five CNS Disorders and their Product Profiling 14
3.1 Endpoints-Major Marketed Drugs of Top Five Central Nervous System Disorders and their Regulatory Approval 14
3.1.1 Alzheimers disease 15
3.1.2 Depression 15
3.1.3 Epilepsy 16
3.1.4 Parkinsons disease 16
3.1.5 Schizophrenia 17

4 Endpoints - Clinical Trials in CNS Disorders Marketed and Pipeline Product Assessments 18
4.1 Alzheimers disease 18
4.1.1 Primary Endpoints used in Alzheimers disease Clinical Trials 19
4.1.2 Secondary Endpoints used in Alzheimers disease Clinical Trials 19
4.1.3 Major Marketed Drugs-Safety and Efficacy Analysis 19
4.1.4 Phase III Clinical Trial Analysis 25
4.1.5 Most Promising Drugs Profiles 41
4.1.6 Phase II Clinical Trial Analysis 45
4.1.7 Terminated Trials Analysis 61
4.2 Depression 62
4.2.1 Primary Endpoints used in Clinical Trials for Depression 63
4.2.2 Secondary Endpoints used in Clinical Trials for Depression 63
4.2.3 Major Marketed Drugs-Safety and Efficacy Analysis 64
4.2.4 Phase III Clinical Trial Analysis 70
4.2.5 Most Promising Drugs Profiles 79
4.2.6 Phase II Clinical Trial Analysis 81
4.2.7 Terminated Trials Analysis 87
4.3 Epilepsy 88
4.3.1 Primary Endpoints used in Clinical Trials for Epilepsy 89
4.3.2 Secondary Endpoints used in Clinical Trials for Epilepsy 90
4.3.3 Major Marketed Drugs-Safety and Efficacy Analysis 90
4.3.4 Phase III Clinical Trial Analysis 96
4.3.5 Most Promising Drugs Profiles 108
4.3.6 Phase II Clinical Trial Analysis 114
4.3.7 Terminated Trials Analysis 122
4.4 Parkinsons disease 123
4.4.1 Primary Endpoints used in Clinical Trials for Parkinsons disease 123
4.4.2 Secondary Endpoints used in Clinical Trials Parkinsons disease 124
4.4.3 Major Marketed Drugs-Safety and Efficacy Analysis 124
4.4.4 Phase III Clinical Trial Analysis 130
4.4.5 Most Promising Drugs Profiles 144
4.4.6 Phase II Clinical Trial Analysis 149
4.4.7 Terminated Trials Analysis 162
4.5 Schizophrenia 163
4.5.1 Primary Endpoints used in Clinical Trials for Schizophrenia 164
4.5.2 Secondary Endpoints used in Clinical Trials for Schizophrenia 164
4.5.3 Major Marketed Drugs-Safety and Efficacy Analysis 165
4.5.4 Phase III Clinical Trial Analysis 171
4.5.5 Most Promising Drugs Profiles 188
4.5.6 Phase II Clinical Trial Analysis 191
4.5.7 Terminated Trials Analysis 200

5 Endpoints - Clinical Trials in CNS Disorders - Company Profiles 201
5.1 Pfizer Inc. 201
5.1.1 Company Profile 201
5.1.2 Major Central Nervous System Disorders Products 201
5.2 GlaxoSmithKline Plc 202
5.2.1 Company Profile 202
5.2.2 Major Central Nervous System Disorders Products 202
5.3 AstraZeneca Plc 203
5.3.1 Company Profile 203
5.3.2 Major Central Nervous System Disorders Products 203
5.4 Sanofi 204
5.4.1 Company Profile 204
5.4.2 Major Central Nervous System Disorders Products 204
5.5 Johnson & Johnson 205
5.5.1 Company Profile 205
5.5.2 Major Central Nervous System Disorders Products 205
5.6 Eli Lilly and Company 207
5.6.1 Company Profile 207
5.6.2 Major Central Nervous System Disorders Products 207
5.7 Novartis AG 208
5.7.1 Company Profile 208
5.7.2 Major Central Nervous System Disorders Products 208
5.8 Abbott Laboratories 210
5.8.1 Company Profile 210
5.8.2 Major Central Nervous System Disorders Products 210
5.9 Forest Laboratories, Inc 211
5.9.1 Company Profile 211
5.9.2 Major Central Nervous System Disorders Products 211
5.10 Eisai Co., Ltd 212
5.10.1 Company Profile 212
5.10.2 Major Central Nervous System Disorders Products 212

6 Endpoints - Clinical Trials in CNS Disorders - Appendix 213
6.1 Market Definitions 213
6.2 Abbreviations 213
6.3 Research Methodology 214
6.3.1 Clinical Trial Design Overview 215
6.3.2 Marketed and Pipeline Products Assessment 215
6.3.3 Company Profiles 215
6.4 Contact Us 216
6.5 Disclaimer 216
6.6 Sources 216

List of Tables


Table 1: Endpoints - Clinical Trials in CNS Disorders, Alzheimers disease, Endpoints for Major Marketed Drugs, Global,1990- 2010 15
Table 2: Endpoints - Clinical Trials in CNS Disorders, Depression, Endpoints for Major Marketed Drugs, Global,1990- 2010 15
Table 3: Endpoints - Clinical Trials in CNS Disorders, Epilepsy, Endpoints for Major Marketed Drugs, Global,1990- 2010 16
Table 4: Endpoints - Clinical Trials in CNS Disorders, Parkinsons disease, Endpoints for Major Marketed Drugs, Global, 1990- 2010 16
Table 5: Endpoints - Clinical Trials in CNS Disorders, Parkinsons disease, Endpoints for Major Marketed Drugs, Global, 1990- 2010 17
Table 6: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase III Trial Molecules, Secondary Endpoints, Global, 2000-2010 32
Table 7: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Ongoing Phase III Trial Molecules, Secondary Endpoints, Global, 2000-2010 40
Table 8: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase II Trial Molecules, Secondary Endpoints, Global, 2000-2010 52
Table 9: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Ongoing Phase II Trial Molecules, Secondary Endpoints, Global, 2000-2010 60
Table 10: Endpoints- Clinical Trials in Central Nervous System Disorders, List of Terminated Drugs for Alzheimers Disease 61
Table 11: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Trial Molecules, Primary Endpoints, Global, 2000-2010 76
Table 12: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Ongoing Phase III Trial Molecules, Primary Endpoints, Global, 2000-2010 79
Table 13: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Ongoing Phase III Trial Molecules, Secondary Endpoints, Global, 2000-2010 79
Table 14: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase II Trial Molecules, Primary Endpoints, Global, 2000-2010 85
Table 15: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Ongoing Phase II Trial Molecules, Primary Endpoints, Global, 2000-2010 87
Table 16: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Ongoing Phase II Trial Molecules, Secondary Endpoints, Global, 2000-2010 87
Table 17: Endpoints- Clinical Trials in Central Nervous System Disorders, List of Terminated Drugs for Depression 87
Table 18: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase III Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010 101
Table 19: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase III Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010 108
Table 20: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase II Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010 119
Table 21: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase II Trial Molecules, Primary Endpoints, Global, 2000-2010 121
Table 22: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase II Trial Molecules, Secondary Endpoints, Global, 2000-2010 121
Table 23: Endpoints- Clinical Trials in Central Nervous System Disorders, List of Terminated Drugs for Epilepsy 122
Table 24: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase III Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010 136
Table 25: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Ongoing Phase III Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010 143
Table 26: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase II Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010 155
Table 27: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Ongoing Phase II Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010 161
Table 28: Endpoints- Clinical Trials in Central Nervous System Disorders, List of Terminated Drugs for Parkinsons Disease 162
Table 29: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010 178
Table 30: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase III Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010 187
Table 31: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase II Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010 194
Table 32: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase II Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010 199
Table 33: Endpoints- Clinical Trials in Central Nervous System Disorders, List of Terminated Drugs for Schizophrenia 200
Table 34: Endpoints- Clinical Trials in Central Nervous Disorders, Pfizer Inc, Major Central Nervous Drugs, 2010 201
Table 35: Endpoints- Clinical Trials in Central Nervous Disorders, GlaxoSmithKline Plc, Major Central Nervous Drugs, 2010 202
Table 36: Endpoints- Clinical Trials in Central Nervous Disorders, AstraZeneca Plc, Major Central Nervous Drugs, 2010 203
Table 37: Endpoints- Clinical Trials in Central Nervous Disorders, Sanofi, Major Central Nervous Drugs, 2010 204
Table 38: Endpoints- Clinical Trials in Central Nervous Disorders, Johnson & Johnson, Major Central Nervous Drugs, 2010 205
Table 39: Endpoints- Clinical Trials in Central Nervous Disorders, Eli Lilly & Company, Major Central Nervous Drugs, 2010 207
Table 40: Endpoints- Clinical Trials in Central Nervous Disorders, Novartis AG, Major Central Nervous Drugs, 2010 208
Table 41: Endpoints- Clinical Trials in Central Nervous Disorders, Abbott Laboratories, Major Central Nervous Drugs, 2010 210
Table 42: Endpoints- Clinical Trials in Central Nervous Disorders, Forest Laboratories, Inc., Major Central Nervous Drugs, 2010 211
Table 43: Endpoints- Clinical Trials in Central Nervous Disorders, Eisai Co., Inc., Major Central Nervous Drugs, 2010 212

List of Figures


Figure 1: Endpoints - Clinical Trials in CNS Disorders, Number of Pipeline products in Phase III Stage of Development, 2011 13
Figure 2: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 24
Figure 3: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase III Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010 25
Figure 4: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase III Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010 26
Figure 5: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 27
Figure 6: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase III Clinical Trials Classified Based on Rare Secondary Endpoints, Global, 2000-2010 28
Figure 7: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 29
Figure 8: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase III Clinical Trials Classified Based on Other Multiple Secondary Endpoints, Global, 2000-2010 30
Figure 9: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Ongoing Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 34
Figure 10: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Ongoing Phase III Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010 35
Figure 11: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Ongoing Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 36
Figure 12: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Ongoing Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 37
Figure 13: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Ongoing Phase III Clinical Trials Classified Based on Other Multiple Secondary Endpoints, Global, 2000-2010 38
Figure 14: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 44
Figure 15: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase II Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010 45
Figure 16: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase II Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010 46
Figure 17: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 47
Figure 18: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase II Clinical Trials Classified Based on Other Secondary Endpoints, Global, 2000-2010 48
Figure 19: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 49
Figure 20: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase II Clinical Trials Classified Based on Other Multiple Secondary Endpoints, Global, 2000-2010 50
Figure 21: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Ongoing Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 54
Figure 22: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Ongoing Phase II Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010 55
Figure 23: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Ongoing Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 56
Figure 24: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Ongoing Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 57
Figure 25: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Ongoing Phase II Clinical Trials Classified Based on Other Multiple Secondary Endpoints, Global, 2000-2010 58
Figure 26: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 69
Figure 27: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010 70
Figure 28: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010 71
Figure 29: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 72
Figure 30: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Clinical Trials Classified Based on Other Secondary Endpoints, Global, 2000-2010 73
Figure 31: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 74
Figure 32: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 80
Figure 33: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase II Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010 81
Figure 34: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase II Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010 82
Figure 35: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 83
Figure 36: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 84
Figure 37: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 95
Figure 38: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase III Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010 96
Figure 39: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 97
Figure 40: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase III Clinical Trials Classified Based on Other Secondary Endpoints, Global, 2000-2010 98
Figure 41: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 99
Figure 42: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 104
Figure 43: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 105
Figure 44: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 106
Figure 45: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 113
Figure 46: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase II Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010 114
Figure 47: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 115
Figure 48: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase II Clinical Trials Classified Based on Other Secondary Endpoints, Global, 2000-2010 116
Figure 49: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 117
Figure 50: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 120
Figure 51: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 129
Figure 52: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase III Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010 130
Figure 53: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase III Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010 131
Figure 54: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 132
Figure 55: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 133
Figure 56: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase III Clinical Trials Classified Based on Rare Multiple Secondary Endpoints, Global, 2000-2010 134
Figure 57: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Ongoing Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 139
Figure 58: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Ongoing Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 140
Figure 59: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Ongoing Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 141
Figure 60: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 148
Figure 61: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase II Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010 149
Figure 62: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase II Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010 150
Figure 63: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 151
Figure 64: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase II Clinical Trials Classified Based on Other Secondary Endpoints, Global, 2000-2010 152
Figure 65: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 153
Figure 66: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase II Clinical Trials Classified Based on Other Multiple Secondary Endpoints, Global, 2000-2010 154
Figure 67: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Ongoing Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 157
Figure 68: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Ongoing Phase II Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010 158
Figure 69: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Ongoing Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 159
Figure 70: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Ongoing Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 160
Figure 71: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 170
Figure 72: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010 171
Figure 73: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010 172
Figure 74: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Other Multiple Primary Endpoints, Global, 2000-2010 173
Figure 75: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 174
Figure 76: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Other Secondary Endpoints, Global, 2000-2010 175
Figure 77: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 176
Figure 78: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Other Multiple Secondary Endpoints, Global, 2000-2010 177
Figure 79: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 184
Figure 80: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 185
Figure 81: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 186
Figure 82: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 190
Figure 83: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase II Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010 191
Figure 84: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase II Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010 192
Figure 85: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 193
Figure 86: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 197
Figure 87: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 198

Upcoming Reports:

Cosmetic Procedures And Products Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Cosmetic procedures include elective surgical as well as nonsurgical procedures performed to reshape normal structures of the body. These procedures and cosmetic products are carried out to improve appearance of an individual thereby boosting self-confidence and self-esteem. The global market for cosmetic procedures and products is expanding both in terms of value and number of procedures performed annually. Several industry experts quote that ageing population, growing acceptance of cosmetic surgery, and interest of people for aesthetic reasons are the prime factors responsible for the...
Poland: glass bottles market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the glass bottles market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the glass bottles market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of...
Nanomaterials In Cosmetic And Personal Care Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2014 - 2020
By - Transparency Market Research
The particles of physical substances which are intentionally prepared with dimension ranges between 1-150 nm are termed as nanomaterials. Properties of nanomaterials may vary from particle of same materials with micron- or mm-scale dimensions. Nanomaterials can also be called as building blocks of nanotechnology in which physical and chemical properties of nanomaterials can be altered for specific applications. Technology in which nanomaterials are used offers extensive improvements in the field of cosmetics and personal care, nanomaterials used in the cosmetics and personal care differ...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Select License type:

Share this report

Related News

Western Africa economies hit by Ebola travel ban
Aug 28, 2014  
With over 1,400 people dead due to the fatal Ebola outbreak in African countries, travel services have either banned or limited operations to the western region, severely hitting economies of the area. Budgetary resources are being utilized rapidly and economic growth has dropped by 4% as international projects and trips have been cancelled. Transport companies have cut off the region...
Fonterra Ties Up With Beingmate to Tap into China’s Baby Food Market
Aug 28, 2014  
Fonterra Co-Operative Group Ltd. will partner with Beingmate Group Co, China’s biggest infant formula manufacturer to increase its reach in the Chinese market. The New Zealand-based company makes this move with the intent to grab a bigger market share in China after it suffered many setbacks in the food-safety scandal last year.   This partnership will also help Beingmate...
Warren Buffet Helps Burger King with Tim Horton Deal
Aug 27, 2014  
Renowned investor Warren Buffet plans to finance Burger King Worldwide Inc.’s acquisition of Tim Hortons Inc., the Canadian coffee chain. Berkshire Hathaway Inc., Warren Buffet’s firm will invest through preferred shares, it is speculated. Nearly 25% of the deal’s financing would be handled by Berkshire. The precise aim for Warren Buffet’s participation is yet...
Anti-UAW Workers to Form Another Union at Volkswagen Plant
Aug 27, 2014  
Employees at the Chattanooga plant of Volkswagen AG are trying to form a union of company’s salaried and hourly workers, as a means to counter the United Auto Workers Local 42 union that was established last month.  The new union is expected to force Volkswagen in rethinking and holding another vote to determine which union is favored by hourly employees. UAV had earlier...
Fairchild Axing 15% of its Workforce with Multiple Plant Closures
Aug 27, 2014  
American semiconductor manufacturer Fairchild has said that it will be laying off nearly 15% of its global workforce following the closure of its facilities in Malaysia, Utah, and Korea. The company will cease the production of five-inch silicon from its plant in Bucheon, Korea. It will also scale down its capacity to produce six-inch wafers. The company will bring these closures into effect...